Erythropoietin analog-human serum albumin fusion
First Claim
Patent Images
1. An EPOa-hSA fusion protein, wherein at least one amino acid residue of the EPOa moiety of the fusion protein is altered such that a site which serves as a site for glycosylation in EPO does not serve as a site for glycosylation in the EPOa.
5 Assignments
0 Petitions
Accused Products
Abstract
Erythropoietin analog-human serum albumin (EPOa-hSA) fusion protein and methods of making and using the fusion protein.
-
Citations
55 Claims
- 1. An EPOa-hSA fusion protein, wherein at least one amino acid residue of the EPOa moiety of the fusion protein is altered such that a site which serves as a site for glycosylation in EPO does not serve as a site for glycosylation in the EPOa.
-
27. An isolated nucleic acid comprising a nucleotide sequence which encodes an EPOa-hSA fusion protein, wherein at least one amino acid residue of the encoded EPOa-hSA which can serve as a glycosylation site in EPO is altered such that it does not serve as a glycosylation site in the EPOa.
-
30. A method of making an EPOa-hSA fusion in a construct or a vector, comprising forming in a construct or vector a sequence in which a nucleic acid which comprises a nucleotide sequence encoding an EPOa is linked in frame to a nucleic acid which comprises a nucleotide sequence encoding human serum albumin.
-
31. A method for making an EPOa-hSA fusion protein comprising:
-
supplying a cell which comprises a nucleic acid which encodes an EPOa-hSA fusion protein and expressing said EPOa-hSA fusion protein from said nucleic acid, thereby making said EPOa-hSA fusion protein. - View Dependent Claims (32)
-
-
33. A method of making an EPOa-hSA fusion protein comprising:
-
providing a transgenic organism which includes a transgene which directs the expression of EPOa-hSA fusion protein;
allowing the transgene to be expressed; and
recovering EPOa-hSA fusion protein. - View Dependent Claims (34, 35, 36, 37, 38)
-
-
39. A method for providing a transgenic preparation which includes an EPOa-hSA fusion protein in the milk of a transgenic mammal comprising:
-
providing a transgenic mammal having an EPOa-hSA fusion protein protein-coding sequence operatively linked to a promoter sequence that results in the expression of the protein-coding sequence in mammary gland epithelial cells, allowing the fusion protein to be expressed, and obtaining milk from the mammal, thereby providing the transgenic preparation.
-
- 40. A transgenic organism, which includes a transgene which encodes an EPOa-hSA fusion protein.
-
46. A pharmaceutical composition having a therapeutically effective amount of an EPOa-hSA fusion protein.
-
47. A method of treating a subject in need of erythropoietin comprising administering a therapeutically effective amount of an EPOa-hSA fusion protein to the subject.
-
51. An erythropoietin analog, wherein four sites which serve as sites for glycosylation in erythropoietin are altered such that they do not serve as glycosylation sites.
-
55. A method for making an EPOa-hSA fusion protein in a cultured cell comprising supplying a cell which includes a nucleic acid which encodes an EPOa-hSA fusion protein, and expressing the EPOa-hSA fusion protein from the nucleic acid, thereby making the EPOa-hSA fusion protein.
Specification